A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
Status:
Not yet recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability,
efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or
MDS/CMML. The study consists of dose escalation (Part I) and dose expansion phase (Part II)